Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | BRAF V600E |
| Therapy | Binimetinib + Cetuximab + Encorafenib |
| Indication/Tumor Type | pancreatic ductal adenocarcinoma |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| BRAF V600E | pancreatic ductal adenocarcinoma | predicted - sensitive | Binimetinib + Cetuximab + Encorafenib | Case Reports/Case Series | Actionable | In a clinical case study, third-line treatment with the combination of Mektovi (binimetinib), Erbitux (cetuximab), and Braftovi (encorafenib) resulted in a partial response with a 74% decrease in primary tumor size in a patient with metastatic pancreatic ductal adenocarcinoma harboring BRAF V600E (PMID: 39461261). | 39461261 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (39461261) | Encorafenib, binimetinib and cetuximab in BRAF V600E-mutated advanced pancreatic adenocarcinoma. | Full reference... |